No more green for VICL...Up in too many days already.
And going higher in after hours! And this rocket hasn't even turned on the burners yet!
Medicare will pay $93,000 for a prostate cancer drug course. How much will they pay for an effective melanoma drug course which is cheaper and more effective that Yervoy. Maybe 30K? That's why the market cap of VICAL could be $1.5 billion with good A-7 results,
AWWW! pity for the soup grapes short-sellers!